Effect of Helicobacter infection on zinc and iron absorption

ISRCTN ISRCTN46133211
DOI https://doi.org/10.1186/ISRCTN46133211
Secondary identifying numbers Fondecyt 1080032
Submission date
14/12/2009
Registration date
06/01/2010
Last edited
06/01/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Daniel López de Romaña
Scientific

Avenida El Libano 5524
Macul
Santiago
7830489
Chile

Study information

Study designRandomised controlled single-blind trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleEffect of Helicobacter infection on zinc and iron absorption: a single blind randomised controlled trial
Study objectives1. Helicobacter pylori infection will have a negative effect on zinc absorption of adults who consume a wheat product fortified with iron and zinc
2. Zinc absorption from a wheat product fortified with zinc oxide will be significantly lower than that from the same product fortified with zinc sulfate in adults with Helicobacter pylori infection
3. Helicobacter pylori infection will have a negative effect on iron absorption of adults who consume a wheat product fortified with iron and zinc
4. Iron absorption from a wheat product fortified with ferrous fumarate will be significantly lower than that from the same product fortified with ferrous sulfate in adults with Helicobacter pylori infection
5. Iron and zinc absorption will be significantly lower in adults with hypochlorhydria compared to those with normal gastric acidity
Ethics approval(s)University of Chile, Institute of Nutrition and Food Technology (INTA) approved on the 20th June 2007 (ref: approval act No. 7)
Health condition(s) or problem(s) studiedHelicobacter pylori infection
InterventionThe urea-C13 breath test will be used to assess Helicobacter pylori (HP) infection. A questionnaire will be used to determine gastrointestinal symptoms and all volunteers who indicate having symptoms will be excluded from the study.

Day 1:
Subjects will provide a fasting urine sample, which will be used as the baseline sample for zinc stable isotope enrichment analysis and as pre-intake sample for gastric pH measurement. Afterwards, they will randomly receive 100 g of bread fortified with either 5.5 mg of ferrous fumarate and 6 mg of zinc oxide or 5.5 mg of ferrous sulfate and 6 mg of zinc sulfate. Bread fortified with ferrous fumarate and zinc oxide will be labelled with 3 µCi of radioisotope 55Fe and 0.5 mg of stable isotope 67Zn and bread fortified with ferrous sulfate and zinc sulfate will be labelled with 1 µCi of radioisotope 59Fe and 0.25 mg of stable isotope 70Zn. A urine sample will be collected after breakfast consumption for gastric pH measurement.

Day 2:
Subjects will receive for breakfast the same bread they received on day 1 but labelled only with a stable isotope of zinc. Total dose of 67Zn for 2 days of study will be 1 mg and total dose of 70Zn for 2 days of study will be 0.5 mg. An additional 0.25 mg of zinc will be added to bread labelled with 70Zn to maintain the dose effect of the isotope constant.

Day 3:
A 20 ml fasting blood sample will be collected to determine hemoglobin, serum iron, TIBC, transferrin saturation, serum ferritin, serum zinc, high sensitivity c-reactive protein, pepsinogen I and pepsinogen II concentrations. A 1 mg dose of stable isotope 68Zn, as sulfate, will be administered intravenously immediately after blood colection. Subjects will receive for breakfast 100 g of bread fortified with those salts they did not receive on Days 1 - 2 and labelled with corresponding iron and zinc isotopes.

Day 4:
Subjects will receive for breakfast the same bread they received on Day 3 but labelled only with a stable isotope of zinc.

Days 7 - 11:
50 ml urine samples will be collected each morning and afternoon for zinc stable isotope enrichment analysis.

Day 17:
A second 20 ml blood sample will be obtained to assess circulating iron radioactivity.

Days 18 - 23:
Subjects will receive daily a proton pump inhibitor (20 mg/d omeprazole). 50 ml urine samples will be collected each morning and afternoon of Days 21 - 23 for zinc stable isotope enrichment analysis.

Day 24:
Subjects will provide a fasting urine sample, which will be used as the baseline sample for zinc stable isotope enrichment analysis and as pre-intake sample for gastric pH measurement. Furthermore, 20 ml of blood will be obtained to assess circulating iron radioactivity and ultrasensitive c-reactive protein, pepsinogen I and pepsinogen II concentrations. A 1 mg dose of stable isotope 68Zn, as sulfate, will be administered intravenously immediately after blood collection. Subsequently, all subjects will receive 100 g of bread fortified with 5.5 mg of iron, as ferrous fumarate, and 6 mg of zinc, as zinc oxide, labelled with 3 µCi of radioisotope 55Fe and 0.5 mg of stable isotope 67Zn. A urine sample will be collected after breakfast consumption for gastric pH measurement.

Day 25:
Subjects will receive for breakfast the same bread they received on Day 21 but labelled only with a stable isotope of zinc.

Days 28 - 32:
50 ml urine samples will be collected each morning and afternoon for zinc stable isotope enrichment analysis.

Day 38:
20 ml of blood will be collected to assess circulating iron radioactivity.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Ferrous sulfate, zinc sulfate, ferrous fumarate, zinc oxide
Primary outcome measureAssessed on days 17 and 38 of the study:
1. Fractional iron absorption, assessed by Eakins and Brown's double-isotope technique
2. Fractional zinc absorption, determined from the ratio of urinary enrichment of oral doses (67Zn and 70Zn) as a proportion of urinary enrichment of intravenous dose (68Zn)
Secondary outcome measures1. Intragastric pH, assessed by the urine acid output test, assessed on days 1 and 24 of the study
2. Pepsinogen I and pepsinogen II will be determined by radioimmunoassay, assessed on day 3 of the study. Haemoglobin, serum iron, TIBC and transferrin saturation, serum ferritin and serum zinc, assessed on day 3 of the study
7. High sensitivity C-reactive protein, assessed on day 3 of the study
Overall study start date01/04/2007
Completion date31/12/2010

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants96
Key inclusion criteria1. Asymptomatic adults
2. Aged 35 - 45 years (women) and aged 25 - 45 years (men)
Key exclusion criteriaGastrointestinal symptoms
Date of first enrolment01/04/2007
Date of final enrolment31/12/2010

Locations

Countries of recruitment

  • Chile

Study participating centre

Avenida El Libano 5524
Santiago
7830489
Chile

Sponsor information

University of Chile, Institute of Nutrition and Food Technology (INTA) (Chile)
University/education

Avenida El Libano 5540
Macul
Santiago
7830489
Chile

Website http://www.inta.cl
ROR logo "ROR" https://ror.org/047gc3g35

Funders

Funder type

Government

Fund for Scientific and Technological Chile (Fondo de Desarrollo Científico y Tecnológico [FONDECYT]) (Chile) (ref: 1080032)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan